The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials. To bring a new drug to market, the FDA requires pharmaceutical

Related Keywords

Louisiana ,United States ,United Kingdom ,Texas ,Boston ,Massachusetts ,California ,Houston ,Canada ,Lake Charles ,San Francisco ,Americans ,Scotland ,American ,Devora Torrence ,Michael Fenne ,Nathalie Sohier ,Lyndon Fullen ,Johns Hopkins ,Mark Blumling ,Yashaswini Singh ,Cecil Nick ,Megan Kalata ,Linda Moore Schipani ,Steven Deeks ,Aaron Kesselheim ,Marcella Alsan ,Fred Schulte ,Danaka Williams ,Goldman Sach ,University Of California ,Johns Hopkins University ,Harvard Kennedy School ,Linkedin ,Harvard Medical School ,Kaiser Family Foundation ,Pfizer ,Astrazeneca ,Kaiser Health News ,Headlands Research ,Clinical Research Associates ,Johnson ,South Texas ,Provident Healthcare ,Centex Studies ,Pamplona Capital Management ,California San Francisco ,Private Equity Stakeholder Project ,Policy Analysis ,